Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juni 2020

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #1871

    Vildt at Genmab med lidt god vilje kan have 5 godkendte produkter på markedet næste år - det er en track record i særklasse

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #1872

      Ja, ikke mange der slår den

      1 Reply Last reply
      0
      • T Offline
        T Offline
        transalp
        wrote on sidst redigeret af
        #1873

        Det er lige ved at det største problem for os er, at de gode nyheder er ved at snuble over hinanden, for at komme ud.. 🙂

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #1874

          InnovaTv208 (ovarie) har Estimated Primary Completion Date : August 31, 2022

          1 Reply Last reply
          0
          • Legolas23L Offline
            Legolas23L Offline
            Legolas23
            wrote on sidst redigeret af
            #1875

            Er det fordi den har ramt endpoints tidligere end ventet det kommer nu ?

            1 Reply Last reply
            0
            • G Offline
              G Offline
              GeorgeBest
              wrote on sidst redigeret af
              #1876

              TV kombinationstudiet i cervical cancer har estimated primary completion date i april 2021https://clinicaltrials.gov/ct2/show/NCT03786081?cond=tisotumab+vedotin&draw=2&rank=8

              1 Reply Last reply
              0
              • G Offline
                G Offline
                GeorgeBest
                wrote on sidst redigeret af
                #1877

                Iovance LN-145 viste ORR på 44% ved ASCO 2019 på 27 pre-treated, recurrent cervical cancer patienter. Bliver nok en hård konkurrent til TV, men er jo nok et års tid bagefter tidsmæssigt https://www.evaluate.com/vantage/articles/news/snippets/asco-2019-iovance-enjoys-pre-asco-bounce

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Stockwatch1
                  wrote on sidst redigeret af
                  #1878

                  Bryan Garnier hæver fair value til 2150 fra 2000. Fortsat Neutral

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Stockwatch1
                    wrote on sidst redigeret af
                    #1879

                    BG: A 24% ORR puts it at the forefront of the cervical space

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Stockwatch1
                      wrote on sidst redigeret af
                      #1880

                      BG: TV seems to have an edge over Keytruda in 2L+ setting

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Stockwatch1
                        wrote on sidst redigeret af
                        #1881

                        BG: This success paves the way for 1L use

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Stockwatch1
                          wrote on sidst redigeret af
                          #1882

                          BG: TV’s reach could go way beyond cervical cancer

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Stockwatch1
                            wrote on sidst redigeret af
                            #1883

                            BG: Genmab on track to become an integrated biopharma company

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Stockwatch1
                              wrote on sidst redigeret af
                              #1884

                              BG: We lift our FV from DKK2,000 to DKK2,150 following the review of our
                              scenario on TV as well as our updated risk-free rate (0.6% vs 1.6%) and risk premium

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #1885

                                thanks @Stockwatch1

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #1886

                                  @GB (not BG 😉 ) that is a difficult treatment though LN 145, isn't it a bit like Car-T?

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #1887

                                    The TIL therapy under investigation in this clinical trial (LN-145) is derived through isolation of a patient’s own naturally occurring TIL from a sample of cancerous tumor removed from the patient. After TIL are extracted from the tumor, they are multiplied in a laboratory until billions of TIL are obtained. https://www.iovance.com/clinical/c-145-04-cervical-carcinoma/

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      GeorgeBest
                                      wrote on sidst redigeret af
                                      #1888

                                      Yes sounds similar to CAR-T

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #1889

                                        24/1 18:05
                                        af E L

                                        Upcoming events – Genmab's route to market,... on TV - (link)

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #1890

                                          ah that link doesn't work like that ,
                                          try https://www.evaluate.com/vantage/articles/events/upcoming-events/upcoming-events-genmabs-route-market-and-late-stage-data

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger